Novartis AG
USE OF CANAKINUMAB
Last updated:
Abstract:
The present invention relates to canakinumab for use in reducing the risk of or preventing recurrent cardiovascular (CV) events in a patient with elevated hsCRP that has suffered myocardial infarction (MI).
Status:
Application
Type:
Utility
Filling date:
24 Aug 2018
Issue date:
25 Jun 2020